Filing Flows › Zomedica (ZOMDF) › R&D spending
Zomedica (ZOMDF) R&D spending by quarter
Zomedica's R&D spending was $1.2M in Q3 2026 (third quarter 2026), +13% from Q2 2026. Over the last 7 quarters it ranged from $1.1M (Q2 2026) to $1.9M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.2M | +13% | -33% |
| Q2 2026 | $1.1M | -7% | -43% |
| Q1 2026 | $1.2M | -30% | -38% |
| Q4 2025 | $1.6M | -8% | — |
| Q3 2025 | $1.8M | -5% | — |
| Q2 2025 | $1.9M | +2% | — |
| Q1 2025 | $1.9M | — | — |
Q3 2026 at a glance
Zomedica, Q3 2026: revenue $9.9M (+22% year over year), operating margin -34.6%, net loss $3.2M, operating cash flow −$2.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is Zomedica's R&D spending?
Zomedica's R&D spending was $1.2M in Q3 2026 (third quarter 2026), +13% from Q2 2026.
How has Zomedica's R&D spending changed?
Over the last 7 quarters it ranged from $1.1M (Q2 2026) to $1.9M (Q2 2025).